Answers are grounded in this paper and cite their sources.
Chemotherapy can trigger pyroptosis in cancer cells, yet the intrinsic regulatory mechanisms governing this process remain largely unclear. Here, we identify MAGEA6 as a phase-separating cancer-testis antigen that establishes a pyroptosis-suppressive condensate barrier in esophageal squamous cell carcinoma (ESCC) by coordinately restraining GSDMD and GSDME cleavage. Mechanistically, cytoplasm-anchored MAGEA6 undergoes phase separation, which impedes the nuclear translocation of TP63, thereby suppressing NLRP1 transcription and subsequent GSDMD activation. Concurrently, MAGEA6 recruits GSDME into dynamic condensates and restricts its Caspase-3-mediated cleavage in response to cisplatin. Disruption of MAGEA6 condensation relieved both inhibitory effects, whereas the MAGEA6 intrinsically disordered region was sufficient to sustain the chemoprotective condensate state. Perturbation of this condensate barrier restored pyroptotic signaling and increased cisplatin sensitivity across multiple ESCC models. These findings identify condensate-mediated spatial control of pyroptosis as a mechanism of chemoprotection and suggest MAGEA6 phase separation as a potential therapeutic target in cisplatin-resistant ESCC.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: